Krystal Biotech
KRYS
140 hedge funds and large institutions have $1.35B invested in Krystal Biotech in 2021 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 56 increasing their positions, 22 reducing their positions, and 21 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
155% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 22
129% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 21
59% more capital invested
Capital invested by funds: $851M → $1.35B (+$499M)
24% more funds holding
Funds holding: 113 → 140 (+27)
4.16% more ownership
Funds ownership: 73.36% → 77.52% (+4.2%)
15% less call options, than puts
Call options by funds: $17.1M | Put options by funds: $20.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$76.9M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$27.6M |
| 3 |
AG
Artal Group
Luxembourg
|
+$11.6M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$11.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$9.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$7.31M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$4.9M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.82M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Principal Financial Group
Des Moines,
Iowa
| – | -$227K | -4,356 | Closed |
|
|
LOIM
152
Liberty One Investment Management
Libertyville,
Illinois
| – | -$141K | -2,697 | Closed |
|
|
PHK
153
Point72 Hong Kong
Hong Kong
| – | -$119K | -2,276 | Closed |
|
154
KBC Group
Brussels,
Belgium
| – | -$103K | -1,975 | Closed |
|
155
Osaic Holdings
Scottsdale,
Arizona
| – | -$35.8K | -615 | -99% |
|
|
PCM
156
Penserra Capital Management
Orinda,
California
| – | -$26K | -510 | Closed |
|
|
CL
157
CSS LLC
Chicago,
Illinois
| – | -$16K | -300 | Closed |
|
|
GRP
158
Global Retirement Partners
San Rafael,
California
| – | -$7K | -125 | Closed |
|
|
QT
159
Quantbot Technologies
New York
| – | -$5K | -100 | Closed |
|
160
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$116 | +2 | New |
|
|
C
161
Covestor
London,
United Kingdom
| – | +$349 | +6 | New |
|
KRYS Hedge Fund Activity: Q4 2021 in Review
140 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2021, worth a combined $1.35B — up 59% from $851M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new KRYS positions and 21 closed out — a net gain of 27 holders — while 56 added to existing stakes and 22 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $76.9M. The largest seller was Redmile Group, cutting an estimated $9.4M.
- 140 institutional investors held Krystal Biotech (KRYS) as of Q4 2021, up from 113 in Q3 2021.
- Funds reported $1.35B of Krystal Biotech stock for Q4 2021, up 59% quarter-over-quarter.
- 48 funds opened new Krystal Biotech positions in Q4 2021 and 21 closed out, a net change of +27 holders.
- The largest Krystal Biotech buyer in Q4 2021 was Point72 Asset Management, an estimated $76.9M added.
- The largest Krystal Biotech seller in Q4 2021 was Redmile Group, an estimated $9.4M sold.
Based on aggregated 13F filings for Q4 2021.